Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etrasimod · Velsipity, APD-334

Small molecule · Modulator of sphingosine 1-phosphate receptor 1 (S1PR1), sphingosine 1-phosphate receptor 4 (S1PR4) and sphingosine 1-phosphate receptor 5 (S1PR5) · developed by Pfizer

Approved FDA, Oct 2023
PFE Developer
1 Registered trials

What is Etrasimod?

Etrasimod is an oral sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4 and 5. It partially and reversibly blocks lymphocyte egress from lymphoid organs, reducing circulating lymphocytes, and is studied in ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Velsipity, APD-334, Non-Interventional Study
Drug type
Small molecule
Targets
sphingosine 1-phosphate receptor 1 (S1PR1), sphingosine 1-phosphate receptor 4 (S1PR4), sphingosine 1-phosphate receptor 5 (S1PR5), sphingosine 1-phosphate receptor 3 (S1PR3) (secondary target)
Mechanism
Modulator of sphingosine 1-phosphate receptor 1 (S1PR1), sphingosine 1-phosphate receptor 4 (S1PR4) and sphingosine 1-phosphate receptor 5 (S1PR5)
Pathways
lymphocyte egress from lymphoid organs, lymphocyte migration into the intestines
Therapy area
Gastroenterology
Developer
Pfizer (PFE)
FDA status
Approved as Velsipity (October 12, 2023), NDA216956 · FDA label
UNII
6WH8495MMH

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03950232 Phase 3 Ulcerative Colitis Active not recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

Other drugs acting on S1PR1 / S1PR4 / S1PR5

More from Pfizer

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Etrasimod

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.